Technology & Platform

Richard DiMarchi, PhD, is one of the world’s leading peptide chemists. He has created a platform technology enabling the rational design of peptides with tunable pharmacological characteristics. 

Native peptide hormones are challenging as drugs because of their short half-lives. Bolus administration of a native hormone is often limited by safety, and well-tolerated doses may be insufficient to achieve the desired pharmacologic effects. By contrast, peptides designed using our platform technology can have significantly greater activity, delayed onset and longer half-lives than native hormones. Importantly, these characteristics can be fine-tuned based on reproducible chemical modification strategies which are central to our platform.